Participants | Patients (children and adults) with moderate-to-severe atopic dermatitis |
Interventions | Systemic immunomodulatory agents, including:Ciclosporin. Methotrexate. Azathioprine. Mycophenolate. Corticosteroids. Dupilumab. Nemolizumab. Lebrikizumab. Ustekinumab. Fezakinumab. Baricitinib. Apremilast. Interferon. Intravenous immunoglobulin. Others, including new agents whose first trials are published between publication of this protocol and our final literature search.
|
Comparators | Any, including placebo. |
Outcomes |
Primary outcomes – efficacy
Change in investigator-reported clinical signs (eg, EASI and o-SCORAD). Change in patient-reported symptoms (eg, POEM).
Primary outcomes - safety
Withdrawal from systemic treatment due to adverse events. Occurrence of serious adverse events.
Secondary outcomes
Change in health-related quality of life (eg, DLQI). Change in itch severity.
|
Design | Randomised controlled trials. |